Tuesday, January 15, 2019 8:11:09 AM
Update Log,
2019-01-15 - Pro 140 Publications, Patents & Statistics (updated),
2019-01-14 - Updated Model (draft), previous 2019-01-03 - Evaluation Model,
2018-07-22 - Comparison HIV-1 Anti-infective antibodies (needs update),
2018-06-26 - Pro 140 Metastatic Cancer Suppression,
2018-06-19 - The return of PRO 140, a CCR5-directed mAb,
2018-06-14 - Pro 140 Covering Scientists,
2018-06-23 - Insider Ownership,
2018-06-22 - PRO 140 SC Combo about to arrive,
2018-02-20 - Pro 140 Phase 2b/3 Pivotal PE Achieved,
Calendar from January 2019 Presentation, PRs & Notes
Pro 140 Important Milestones for HIV & Cancer 2019
- DONE: CD02 Pivotal Phase 3 Endpoint Achieved (ASM Microbe late breaker) (Source: CYDY)
- DONE: Full CD02 Trial Data Disclosure via 7/16 PR.
- DONE: Medical Conference Presentations (CROI and ASM Microbe) (Source: CYDY)
- DONE: Publication of Monotherapy (Phase 2b, CD01) (Source: CYDY)
- DONE: 150pt 24weeks 350mg safety data, 89 CD03 pts from 2017-10-17 completed on 2018-04-03 (7/17 CC + Deduction)
- DONE: Orphan Drug Designation for GvHD (ODD) granted by FDA (Source: CYDY)
- DONE: Published GvHD Preclinical Studies (Source: CYDY)
- DONE: Colon Cancer Animal Study Statistical Significant Results (8/15 CYDY PR)
- DONE: Complete Acquisition of ProstaGene (All share deal for Pestell&Co, how much?) (Source: CYDY)
- DONE: Colon Cancer Animal Study (Source: CYDY)
- DONE: CD03 Monotherapy 700mg w/ ~92% responder rate, 24/26 for 12 weeks, VL rebound (Source: CYDY)
- DONE: Triple Negative Breast Cancer (TNBC) Phase 1b/2 IND-Protocol filed & FDA approved (Source: CYDY)
- LATE: Publication Studies – CD02 Combo Primary Endpoint Study (Source: CYDY 7/19 CC)
- LATE: GvHD data review of 10(?) additional pts by iDMC soon (CYDY 7/19 CC)???
- 1Q19: Triple Negative Breast Cancer (TNBC) Pase 1b/2 first patient injected (Source: CYDY)
- 1Q19: Late Breaker at CROI - Combination therapy - Monotherapy - Will apply (Source: CYDY)
- 1H19: BLA Submission Completion (Source: CYDY)
- 1H19: Large Pharma discussion for potential licensing or partnering (Source: CYDY)
- 1H19: Triple Negative Breast Cancer (TNBC) Pase 1b/2 interim results (Source: CYDY)
- 1H19: IND-Protocol for colon cancer Phase 2 (Source: CYDY)
- 2019: Prognostic test licensed (Source: CYDY)
- 2020: Revenue potential of about $480M (Source: CYDY)
+++
Latest PR & Social Media
CYDY Published three interview updates
- 2019-01-14 Potential Breakthroughs, CYDY is Working Towards in HIV and Cancer Treatment – audio copy on youtube
-- $180M raised, only 10-15% more required for BLA submission
-- “mechanism working for any cancer that has CCR5, will be effective”
-- “50% of the breast cancer that metastasized have CCR5”
-- “The (cancer) market for such product could be in trillions, not billions, but trillions”, said Pourhassan
-- “non-dilutive fundraising is around the corner people in Europe are asking for Pro 140 .. to use it in the trial .. they want to collaborate with us they want to use Pro 140 as a sustaining mechanism… they are talking about licensing for the HIV and cancer with smaller and bigger pharma”, said Pourhassan
- 2019-01-11 CytoDyn aims to be ‘paradigm-shifting’ in cancer management with its platform drug leronlimab
- 2019-01-07 Monoclonal antibody HIV treatment w potential FDA approval in 2019
+++
Recent CYDY News
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 08/15/2024 09:21:30 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/22/2024 01:00:58 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:17:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 07/09/2024 09:16:28 PM
- Form SC TO-I/A - Tender offer statement by Issuer: [Amend] • Edgar (US Regulatory) • 07/09/2024 09:16:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 12:46:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM
PickleJar Launches National "Get on the Bus" Campaign, Unveils Thompson Square Tour Bus Wrap • PKLE • Sep 4, 2024 7:17 AM